Loading organizations...
Loading organizations...
Cansativa Group is a technology company.
Cansativa Group has raised $15.0M across 1 funding round.
Cansativa Group has raised $15.0M in total across 1 funding round.
Cansativa Group is a pioneer and established wholesaler for medical cannabis, providing high-quality products and facilitating access for pharmacies, doctors, and patients.
Cansativa Group is a leading German technology-driven pharmaceutical company specializing in the distribution and platform-based access to medical cannabis products. It builds a comprehensive B2B platform that connects pharmacies, suppliers, and producers to facilitate easy, fast, and reliable access to high-quality cannabis brands and products. Serving pharmacies, pharmaceutical wholesalers, and ultimately patients, Cansativa addresses the challenge of simplifying access to modern cannabis-based therapies while professionalizing the medical cannabis market in Germany and Europe. The company has shown strong growth momentum, with a market share of about 20%, over 2,000 active customers, a portfolio exceeding 400 SKUs, and net sales surpassing €17 million in 2023[1][3][4].
Founded in 2017 by brothers Jakob and Benedikt Sons along with their father, Cansativa originated in response to new German regulations facilitating medicinal cannabis access. Initially starting as a wholesaler in Frankfurt am Main in 2018, the company evolved into a platform provider by 2021, expanding its role from distribution to offering integrated product information and availability data. This evolution marked a strategic shift from traditional wholesale to a brand-oriented model, positioning Cansativa as a pioneer and industry leader in the medical cannabis sector in Germany[1][4][5].
Cansativa rides the growing trend of legalization and professionalization of medical cannabis in Europe, particularly Germany’s expanding market. The timing is favorable due to increasing regulatory acceptance, rising patient demand for cannabis-based therapies, and the need for reliable, transparent supply chains. By creating a digital platform that integrates suppliers, pharmacies, and patients, Cansativa is shaping the ecosystem toward greater efficiency, trust, and accessibility. Its role as a technology enabler and market consolidator influences the broader pharmaceutical and wellness sectors by setting new standards for cannabis distribution and therapy access[1][4][6].
Looking ahead, Cansativa aims to solidify its position as the "Amazon of cannabis" in Europe by expanding its platform capabilities, product portfolio, and geographic reach. Trends such as increasing legalization, patient acceptance, and digital health integration will shape its growth trajectory. The company’s continued focus on innovation, regulatory compliance, and strategic partnerships (e.g., supply agreements with EU-GMP certified producers) will likely enhance its influence in the medical cannabis market and broader pharmaceutical ecosystem. As the industry matures, Cansativa’s platform model may become a blueprint for cannabis distribution and access across Europe[6][7].
Cansativa Group has raised $15.0M in total across 1 funding round.
Cansativa Group's investors include Casa Verde Capital, Alluti, Argonautic Ventures.
Cansativa Group has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series B in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $15.0M Series B | Casa Verde Capital | Alluti, Argonautic Ventures |